Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study

Open access

Abstract

BACKGROUND: Clinical prognostic groupings for localised prostate cancers are imprecise, with 30-50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and microenvironmental indices in prostate cancer to improve risk stratification and complement clinical prognostic factors. METHODS: We used DNA-based indices alone or in combination with intra-prostatic hypoxia measurements to develop four prognostic indices in 126 low-risk to intermediate-risk patients (Toronto cohort) who will receive image-guided radiotherapy. We validated these indices in two independent cohorts of 154 (Memorial Sloan Kettering Cancer Center cohort [MSKCC] cohort) and 117 (Cambridge cohort) radical prostatectomy specimens from low-risk to high-risk patients. We applied unsupervised and supervised machine learning techniques to the copy-number profiles of 126 pre-image-guided radiotherapy diagnostic biopsies to develop prognostic signatures. Our primary endpoint was the development of a set of prognostic measures capable of stratifying patients for risk of biochemical relapse 5 years after primary treatment. FINDINGS: Biochemical relapse was associated with indices of tumour hypoxia, genomic instability, and genomic subtypes based on multivariate analyses. We identified four genomic subtypes for prostate cancer, which had different 5-year biochemical relapse-free survival. Genomic instability is prognostic for relapse in both image-guided radiotherapy (multivariate analysis hazard ratio [HR] 4·5 [95% CI 2·1-9·8]; p=0·00013; area under the receiver operator curve [AUC] 0·70 [95% CI 0·65-0·76]) and radical prostatectomy (4·0 [1·6-9·7]; p=0·0024; AUC 0·57 [0·52-0·61]) patients with prostate cancer, and its effect is magnified by intratumoral hypoxia (3·8 [1·2-12]; p=0·019; AUC 0·67 [0·61-0·73]). A novel 100-loci DNA signature accurately classified treatment outcome in the MSKCC low-risk to intermediate-risk cohort (multivariate analysis HR 6·1 [95% CI 2·0-19]; p=0·0015; AUC 0·74 [95% CI 0·65-0·83]). In the independent MSKCC and Cambridge cohorts, this signature identified low-risk to high-risk patients who were most likely to fail treatment within 18 months (combined cohorts multivariate analysis HR 2·9 [95% CI 1·4-6·0]; p=0·0039; AUC 0·68 [95% CI 0·63-0·73]), and was better at predicting biochemical relapse than 23 previously published RNA signatures. INTERPRETATION: This is the first study of cancer outcome to integrate DNA-based and microenvironment-based failure indices to predict patient outcome. Patients exhibiting these aggressive features after biopsy should be entered into treatment intensification trials. FUNDING: Movember Foundation, Prostate Cancer Canada, Ontario Institute for Cancer Research, Canadian Institute for Health Research, NIHR Cambridge Biomedical Research Centre, The University of Cambridge, Cancer Research UK, Cambridge Cancer Charity, Prostate Cancer UK, Hutchison Whampoa Limited, Terry Fox Research Institute, Princess Margaret Cancer Centre Foundation, PMH-Radiation Medicine Program Academic Enrichment Fund, Motorcycle Ride for Dad (Durham), Canadian Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)71021-6

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Kaplan-Meier analysis of biochemical-relapse free survival for patients stratifi ed by tumour subtype
Figure 1 Kaplan-Meier analysis of biochemical-relapse free survival for patients stratifi ed by tumour subtypeCC-BY · From the PDF
Figure 2 Genomic instability (PGA) as an independent prognostic factor in patients with prostate cancer PGA is not a proxy for Gleason grade (A), clinical T category (B), or PSA (C; n=336, Toronto IGRT, Memorial Sloan Kettering Cancer Center, and Cambridge low-risk to intermediate-risk National Comprehensive Cancer Network classifi cation risk groups combined). p values were obtained by two-tailed Kruskal-Wallis tests (A) and Mann-Whitney tests (B-C). Horizontal lines show median PGA values per group. IGRT=image-guided radiotherapy. RP=radical prostatectomy.
Figure 2 Genomic instability (PGA) as an independent prognostic factor in patients with prostate cancer PGA is not a proxy for Gleason grade (A), clinical T category (B), or PSA (C; n=336, Toronto IGRT, Memorial Sloan Kettering Cancer Center, and Cambridge low-risk to intermediate-risk National Comprehensive Cancer Network classifi cation risk groups combined). p values were obtained by two-tailed Kruskal-Wallis tests (A) and Mann-Whitney tests (B-C). Horizontal lines show median PGA values per group. IGRT=image-guided radiotherapy. RP=radical prostatectomy.CC-BY · From the PDF
Figure 3 Kaplan-Meier analysis of PGA as a prognostic factor for biochemical treatment failure in image-guided radiotherapy patients (A) and those undergoing radical prostatectomy in the low-risk and intermediate-risk group (B) and the full group (C)
Figure 3 Kaplan-Meier analysis of PGA as a prognostic factor for biochemical treatment failure in image-guided radiotherapy patients (A) and those undergoing radical prostatectomy in the low-risk and intermediate-risk group (B) and the full group (C)CC-BY · From the PDF
Figure 4 Kaplan-Meier analysis of biochemical relapse for patients stratifi ed by PGA and hypoxia values
Figure 4 Kaplan-Meier analysis of biochemical relapse for patients stratifi ed by PGA and hypoxia valuesCC-BY · From the PDF
Figure 5 A prognostic DNA signature for prostate cancer
Figure 5 A prognostic DNA signature for prostate cancerCC-BY · From the PDF
Figure 6 Training and comparison of random forest signatures for 23 previously published RNA signatures for biochemical relapse-free survival We trained a clinical model (in green) with clinical variables: pretreatment PSA, biopsy-based Gleason score, and T category. We compared our DNA-based signature (CNA_RF, shown in red) with these signatures in the 108 Memorial Sloan Kettering Cancer Center patients with information about both mRNA and CNA. The DNA, RNA, and clinical signatures were trained in a cohort of 293 lowrisk to intermediate-risk patients with prostate cancer (A) and 1299 low-risk to high-risk patients (B), including some with locally advanced disease. In cases where more than one study published more than one signature, only the best performing signature is shown. CNA=copy number alterations. AUC=area under the receiver operator curve.
Figure 6 Training and comparison of random forest signatures for 23 previously published RNA signatures for biochemical relapse-free survival We trained a clinical model (in green) with clinical variables: pretreatment PSA, biopsy-based Gleason score, and T category. We compared our DNA-based signature (CNA_RF, shown in red) with these signatures in the 108 Memorial Sloan Kettering Cancer Center patients with information about both mRNA and CNA. The DNA, RNA, and clinical signatures were trained in a cohort of 293 lowrisk to intermediate-risk patients with prostate cancer (A) and 1299 low-risk to high-risk patients (B), including some with locally advanced disease. In cases where more than one study published more than one signature, only the best performing signature is shown. CNA=copy number alterations. AUC=area under the receiver operator curve.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

  • Integrative Clinical Genomics of Advanced Prostate Cancer

    Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645

    “Although certain primary prostate cancer alterations or signatures have prognostic clinical significance (Hieronymus et al., 2014; Lalonde et al., 2014), the therapeutic impact of primary prostate cancer genomic events has not yet been realized.”
  • The Molecular Taxonomy of Primary Prostate Cancer

    Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110

    “…also have varying degrees of DNA copy-number alteration; indolent and low-Gleason tumors have few alterations, whereas more aggressive primary and metastatic tumors have extensive burdens of copy-number alteration genome-wide (Taylor et al., 2010, Hieronymus et al., 2014, Lalonde et al., 2014).”
    BackgroundSelf-citation
  • “…(Bolli et al., 2014); lung adenocarcinomas (de Bruin et al., 2014; Zhang et al., 2014); prostate (Gundem et al., 2015; Ju et al., 2014); bladder (Lamy et al., 2016); colorectal adenocarcinomas (Uchi et al., 2016); liver hepatocellular carcinoma (Xue et al., 2016); esophageal squamous cell…”
  • Prostate cancer

    Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090

    Self-citation
  • Molecular landmarks of tumor hypoxia across cancer types

    Bhandari, V., Hoey, C., Liu, L. Y., Lalonde, E., Ray, J., Livingstone, J., Lesurf, R., Shiah, Y.-J., Vujcic, T., Huang, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0318-2 · Cited by 678

    Self-citation

See all 345

Metadata

Authors
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., Zafarana, G., Warren, A. Y., Meng, X., Thoms, J., Grzadkowski, M. R., Berlin, A., Have, C. L., Ramnarine, V. R., Yao, C. Q., Malloff, C. A., Lam, L. L., Xie, H., Harding, N. J., Mak, D. Y. F., Chu, K. C., Chong, L. C., Sendorek, D. H., P'ng, C., Collins, C. C., Squire, J. A., Jurisica, I., Cooper, C., Eeles, R., Pintilie, M., Dal Pra, A., Davicioni, E., Lam, W. L., Milosevic, M., Neal, D. E., van der Kwast, T., Boutros, P. C., & Bristow, R. G.
Affiliations
  • Ontario Institute for Cancer Research (CA)
  • University of Miami (US)
  • University Health Network (CA)
  • University of Cambridge (GB)
  • Addenbrooke's Hospital (GB)
  • BC Cancer Agency (CA)
  • University of British Columbia (CA)
  • Universidade de São Paulo (BR)
  • University of East Anglia (GB)
  • National Health Service (GB)
  • University of Toronto (CA)
Corresponding author
Bristow, Robert G
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2014-12
Volume
15
Issue
13
Pages
1521-1532
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2158872144
Cited by
342
References
36
Citations by year
2026: 9 · 2025: 17 · 2024: 26 · 2023: 24 · 2022: 30 · 2021: 40 · 2020: 29 · 2019: 31 · 2018: 38 · 2017: 35 · 2016: 39 · 2015: 22 · 2014: 2
FWCI
26.05
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Oncology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion)
Funders
Prostate Cancer Canada and is funded by the Movember Foundation (grant number RS2014-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
prostate cancer, biochemical recurrence, tumor microenvironment, intratumoral hypoxia, genomic instability, copy number profiles, genomic subtypes, risk stratification, image-guided radiotherapy, radical prostatectomy, prognostic score, localized prostate cancer, machine learning prediction
MeSH terms
DNA, Neoplasm, Follow-Up Studies, Humans, Male, Neoplasm Recurrence, Local, Prognosis, Prostatic Neoplasms, Retrospective Studies, Time Factors, Biomarkers, Tumor, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71021-6
The paper
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., Zafarana, G., Warren, A. Y., Meng, X., Thoms, J., Grzadkowski, M. R., Berlin, A., Have, C. L., Ramnarine, V. R., Yao, C. Q., . . . Bristow, R. G. (2014). Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71021-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.